Life Sciences

Swiss Life Sciences – ready for R&D 2030?

Digitalization and societal shifts are pushing Life Sciences to the brink of transformation. Over the next decade, successful players will need to redefine their R&D activities in order to rein in expenses, respond to shorter product lifecycles and seize opportunities of personalized medicine.
2

Swap, don’t sell: Driving value through asset swaps

The Swiss Pharmaceuticals sector produced four USD1 billion+ deals in the first half of 2018. This is not surprising given the efforts by Pharmaceuticals and Life Sciences businesses to push new boundaries and continuously innovate.

Expanding right into Europe

Innovation is the life source of Life Sciences. But strategic and meticulous planning is key to commercial success, especially when entering a new regional market.

Das neue Heilmittelgesetz: Fluch oder Segen?

Das neue Heilmittelgesetz wurde zwar bereits vor 2 Jahren verabschiedet, in Kraft tritt es jedoch vermutlich erst am 1. Januar 2019, nach Abschluss des umfangreichen Vernehmlassungsverfahrens. Ziel und Zweck des Gesetzes ist die Regelung der Zulassung und des Vertriebs von Arzneien.
2

EU Medical Device Regulation: What’s the impact?

Following various incidents in recent years, the control mechanisms for medical devices are being tightened throughout Europe with the new EU Medical Device Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR). What is the impact of these EU regulations for Switzerland and how do you ensure compliance on your end by the time the transition period ends?
4

Digitalization reshuffles the deck in life sciences industry

Life science companies will need an integrated digital data strategy with internal and external processes to stay successful and to make use of the available data. At the center of the new life sciency ecosystem is the patient centric view.
2